Export-oriented API, herbal extraction & nutraceutical manufacturer

business@chemicraftpharma.comInvestor Relations

ChemiCraftPharmaceuticals Pvt. Ltd.

Serving regulated and semi-regulated markets worldwide

Around 80% export orientation, with entry routes matched to each region’s regulatory pathway.

Target geographies

Eight geographies, sequenced by regulatory readiness

India (Domestic)All herbal APIs, nicotine, Vitamin D3Route: Direct pharma company salesFY 2027–28
USANicotine USP, Curcumin, BoswelliaRoute: USFDA-DMF + US distributorFY 2028–29
Southeast AsiaHerbal extracts, nutraceuticalsRoute: Regional distributorsFY 2028–29
Gulf / GCCHerbal APIs, Vitamin D3, SennaRoute: Gulf pharma distributorsFY 2028–29
European UnionCEP-registered APIs, botanical APIsRoute: EU agent + CEP certificationFY 2029–30
United KingdomNicotine APIs, botanical extractsRoute: MHRA registration + UK agentFY 2029–30
AfricaNeem, Senna, Tulsi, generic APIsRoute: African pharma importersFY 2029–30
Japan / South KoreaLicorice actives, Glabridin, CoQ10Route: Cosmetic channelsFY 2030–31
Business model

Three revenue pillars

A B2B model selling directly to formulators, brands and contract manufacturers.

  • Domestic API supply — certified APIs for tablets, capsules, patches and liquids.
  • Export sales — direct and via distribution partners to USA, EU, UK, Southeast Asia, Gulf and Africa.
  • Contract manufacturing (CRAMS) — custom extraction and purification for global pharma.
  • Long-term supply contracts; long qualification cycles create strong customer stickiness.
Who we serve

Customer segments

Generic pharmaceutical manufacturersMultinational pharma (CRAMS)Nutraceutical & supplement brandsCosmetic & personal-care companiesAnimal health & veterinaryFood & beverage companiesNRT product companies
Market context

Why herbal & specialty APIs, why India, why now

USD 245 BnGlobal API market (2024), heading to USD 370–400 Bn by 2030
USD 16 BnIndia API market, ~11% CAGR
USD 550 BnGlobal herbal medicine market by 2030
USD 7.1 BnGlobal nicotine API market by 2030

India supplies roughly half of global generic medicine demand, and China+1 diversification is moving multinationals toward Indian sourcing. Chemicraft’s first-mover multi-product herbal API portfolio, technology edge and cost base are built for that shift.

Become a Chemicraft supply partner

Share your product, grade and volume requirements to begin supplier qualification.

Request a quotation